Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Icu Medical (ICUI) Common Equity (2016 - 2025)

Historic Common Equity for Icu Medical (ICUI) over the last 17 years, with Q3 2025 value amounting to $2.1 billion.

  • Icu Medical's Common Equity rose 383.99% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 383.99%. This contributed to the annual value of $2.0 billion for FY2024, which is 744.91% down from last year.
  • Latest data reveals that Icu Medical reported Common Equity of $2.1 billion as of Q3 2025, which was up 383.99% from $2.1 billion recorded in Q2 2025.
  • Icu Medical's 5-year Common Equity high stood at $2.2 billion for Q1 2022, and its period low was $1.5 billion during Q1 2021.
  • Its 5-year average for Common Equity is $2.0 billion, with a median of $2.1 billion in 2024.
  • Per our database at Business Quant, Icu Medical's Common Equity soared by 4327.64% in 2022 and then plummeted by 744.91% in 2024.
  • Icu Medical's Common Equity (Quarter) stood at $1.6 billion in 2021, then rose by 29.32% to $2.1 billion in 2022, then grew by 1.6% to $2.1 billion in 2023, then decreased by 7.45% to $2.0 billion in 2024, then grew by 8.24% to $2.1 billion in 2025.
  • Its Common Equity stands at $2.1 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.0 billion for Q1 2025.